Occurrence of diabetic ketoacidosis and autoimmune thyroiditis in a patient treated with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
10.3350/kjhep.2010.16.2.187
- Author:
Yun Nah LEE
1
;
Soung Won JEONG
;
Jae Hee LIM
;
Yang Seon RYU
;
Seong Ran JEON
;
Sang Kyun KIM
;
Jae Young JANG
;
Young Seok KIM
;
Boo Sung KIM
;
Mi Oh ROH
Author Information
1. Institute for Digestive Research, Endocrinology, Soonchunhyang University College of Medicine, Seoul, Korea. jeongsw@hosp.sch.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Hepatitis C, chronic;
Interferon Alfa-2b;
Diabetes Mellitus, type 1;
Thyroiditis, autoimmune
- MeSH:
Adult;
Antiviral Agents/*adverse effects/therapeutic use;
Diabetic Ketoacidosis/drug therapy/*etiology;
Drug Therapy, Combination;
Female;
Hepatitis C, Chronic/*drug therapy;
Humans;
Insulin/therapeutic use;
Interferon Alfa-2b/*adverse effects/therapeutic use;
Polyethylene Glycols/*adverse effects/therapeutic use;
Ribavirin/*adverse effects/therapeutic use;
Thyroiditis, Autoimmune/drug therapy/*etiology;
Thyroxine/therapeutic use
- From:The Korean Journal of Hepatology
2010;16(2):187-191
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Combined pegylated interferon and ribavirin therapy for chronic hepatitis C infection cause a wide range of side effects, including flu-like syndrome, hematological abnormalities, cardiovascular symptoms, gastrointestinal symptoms, pulmonary dysfunction, depression, and retinopathy. Interferon-alpha has been shown to be related to the development of various autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, and type 1 diabetes mellitus (DM). Type 1 DM and thyroid disease respectively develop in 0.08~2.61% and 10~15% of patients treated with combined interferon-alpha and ribavirin for chronic hepatitis C. The coexistence of type 1 DM and autoimmune thyroiditis was rarely reported. We report a case of a 33-year-old female patient with chronic hepatitis C who simultaneously developed diabetic ketoacidosis and autoimmune thyroiditis after treatment with pegylated interferon-alpha 2b and ribavirin.
